Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECIOUS study of Amlessa and Co-Amlessa in newly diagnosed or uncontrolled hypertension
2017-001596-23Phase 3Completed
- Sponsor
- Krka
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of amlodipine + perindopril in essential hypertension (2 arms), sponsored by Krka. Primary endpoint: Responder rate after 16 weeks. Started Oct 2017; status: completed.
02
Drugs
amlodipine + perindopril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2017-001596-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001596-23.